NX-09

NX-09 is a preclinical recombinant fusion protein developed by Beijing Neoletix Biological Technology for the treatment of a broad range of primary and metastatic tumors. Developed using the company's proprietary Neo-Fusion technology platform, NX-09 is designed to modulate the tumor microenvironment by delivering an interleukin-associated signal. While the specific interleukin component is currently identified by the placeholder 'IL-X' in public pipeline disclosures, the drug is intended to function as an immunotherapy that enhances anti-tumor immune responses. The fusion protein modality is engineered to improve the therapeutic index and pharmacokinetic profile of the cytokine payload, potentially offering superior efficacy and safety compared to native interleukin therapies.